- Surmodics, Inc. delivered an earnings per share (EPS) of 7 cents in the second quarter of fiscal 2024, beating the Zacks Consensus Estimate of a loss of 36 cents per share by 119.4%.
- The company registered revenues of $31.9 million in the fiscal second quarter, up 18% year over year, surpassing the Zacks Consensus Estimate by 11%.
- Surmodics has revised its financial outlook for fiscal 2024 with projected revenues in the range of $122 million-$124 million, representing a decrease of 8-6% over the comparable prior-year period.
Surmodics, Inc. reports impressive second quarter results for fiscal 2024 with a significant increase in earnings per share and revenue. The company also revises its financial outlook for fiscal 2024.
Surmodics Q2 Fiscal 2024 Earnings
Surmodics, Inc. delivered an earnings per share (EPS) of 7 cents in the second quarter of fiscal 2024, a significant improvement against the year-ago quarter’s loss of 40 cents per share. The metric beat the Zacks Consensus Estimate of a loss of 36 cents per share by 119.4%. GAAP EPS for the quarter was 2 cents, narrower than the year-earlier loss of 55 cents per share.
Revenues in Detail
Surmodics registered revenues of $31.9 million in the fiscal second quarter, up 18% year over year. The figure surpassed the Zacks Consensus Estimate by 11%. The top line was boosted by solid year-over-year product sales growth from the Medical Device business. Excluding SurVeil drug-coated balloon (DCB) license fee revenues, total revenues increased 19% year over year to $30.9 million.
Segmental Analysis
Surmodics operates via two reportable segments — Medical Device and IVD. In the reported quarter, sales in the Medical Device segment summed $24.8 million, up 26% from the year-ago quarter. Excluding SurVeil DCB license fee revenues, Medical Device revenues increased 29% to $23.7 million year over year. This figure compares to our Medical Device fiscal second-quarter revenue projection of $22.5 million. Medical Device revenue growth was primarily driven by product sales of $11.1 million, up 40% year over year.
Margin Trend
In the quarter under review, Surmodics’ gross profit increased 15.8% to $24.9 million. However, the gross margin contracted 120 basis points to 77.7%. Selling, general & administrative expenses increased 0.9% to $13.1 million. Research and development expenses increased 1% year over year to $8.8 million. Operating expenses, excluding product costs, decreased 14% to $24.2 year over year.
Conclusion
Surmodics exited the second quarter of fiscal 2024 with better-than-expected results. The solid uptick in the overall top line and bottom line was impressive. The company registered robust revenues from its medical device and its primary sources, which was encouraging. However, the gross margin contraction does not bode well for Surmodics. Continued adverse impacts due to supply-chain challenges also raise our apprehension.
